Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch, Licensing & Alliances: Amgen Places $66m Bet On Genetic Sequencing

Executive Summary

Already partnered with Oxford Nanopore through its acquisition of deCODE Genetics, Amgen invests in the UK biotech to enhance its genomic capabilities. Aclaris licenses dermatology product Rhofade from Allergan. Other recent licensing and alliance deals... 

Advertisement

Related Content

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets
AbbVie Buys In On Morphic’s Oral Integrin Inhibitors, To Tune Of $100m
Tie-Up Moves Kangstem's Novel Stem Cell Therapy Towards Globalization
BMS, Compugen Pursue Multiple Checkpoint Inhibitions In Antibody Collaboration
Vertex’s Danish Reimbursement Deal Brings Budget Predictability
Sandoz And AbbVie Biosimilar Humira Settlement: What Does It Mean?
Carrick Targets Ovarian Cancer With BTG Deal, Entices Celgene’s Former Top Deal Maker
Ionis Catches The Eye With New Roche Alliance
Almirall Inks 'Transformational Deal' Buying Allergan's US Derma Portfolio
Oxford Nanopore Hits £1.5bn Valuation With Latest £100m Round

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124030

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel